GlassScriptPhysician profile
Brad William Hammon
NPI 1114388204
$7,158.16
in general payments reported to CMS, 2019-2025
27 companies · $1,894 in 2025
The $1,894 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $608 · 2020: $233 · 2021: $196 · 2022: $900 · 2023: $1,649 · 2024: $1,678 · 2025: $1,894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,027 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,027.27 |
| Education | $193.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,541.82 | 2019-2025 | |
| Lilly USA, LLC | $853.93 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Novartis Pharmaceuticals Corporation | $693.95 | 2021-2025 | |
| Genzyme Corporation | $493.12 | 2022-2025 | |
| Janssen Biotech, INC. | $483.59 | 2023-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $431.84 | 2022-2025 | Ilumya, Absorica Ld, Winlevi |
| Leo Pharma INC. | $374.00 | 2022-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $298.64 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $275.99 | 2019-2025 | Dupixent, Libtayo |
| Ucb, INC. | $255.03 | 2021-2025 | Bimzelx |
| Merz North America, INC. | $215.24 | 2022 | |
| Amgen INC. | $168.56 | 2023-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $166.51 | 2023-2025 | Zoryve |
| Genentech USA, INC. | $140.37 | 2019 | |
| Dermavant Sciences, INC. | $131.07 | 2022-2024 | Vtama |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $125.00 | 2019 | |
| Galderma Laboratories, L.P. | $111.44 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $89.90 | 2023-2025 | Jublia |
| Pfizer INC. | $74.25 | 2023-2024 | |
| Hill Dermaceuticals, INC. | $62.58 | 2023-2024 | Tolak |
| Organon LLC | $39.16 | 2025 | Vtama |
| Almirall LLC | $30.86 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.79 | 2025 | Spevigo |
| Biocon Biologics INC | $23.95 | 2025 | Yesintek |
| Blueprint Medicines Corporation | $21.13 | 2023 | |
| Mayne Pharma Commercial LLC | $14.81 | 2020 | |
| Strata Skin Sciences, INC. | $14.63 | 2025 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brad Hammon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.